Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 3 1

Status

Completed 13Terminated 5Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 2Breast 2Thoracic 1

Conditions

Melanoma 2Breast Neoplasms 2Lung Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Terminated × tanespimycin × Clear all
NCT01228435 2017-12-04

IPI-504 in NSCLC Patients With ALK Translocations

Massachusetts General Hospital

Phase 2 Terminated
3 enrolled 5 charts
Thoracic

Lung Neoplasms

NCT00096109 2017-01-16

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
11 enrolled 6 charts
Breast

Breast Neoplasms

NCT00087386 2013-04-10

Tanespimycin in Treating Patients With Stage III-IV Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
50 enrolled
Dermatologic

Melanoma

NCT00817362 2012-12-11

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
29 enrolled
Breast

Breast Neoplasms

NCT00627419 2012-12-10

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡